## Mallory L Hacker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7898251/publications.pdf

Version: 2024-02-01

all docs

1163117 888059 23 313 8 17 citations g-index h-index papers 23 23 23 356 docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease. Neuromodulation, 2022, 25, 846-853.	0.8	6
2	Deep Brain Stimulation in Early-Stage Parkinson's Disease: Patient Experience after 11 Years. Brain Sciences, 2022, 12, 766.	2.3	3
3	A comparative evaluation of telehealth and direct assessment when screening for spasticity in residents of two long-term care facilities. Clinical Rehabilitation, 2021, 35, 589-594.	2.2	8
4	The Minimum Data Set: An Opportunity to Improve Spasticity Screening. Journal of the American Medical Directors Association, 2021, 22, 608-612.	2.5	1
5	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. Geriatrics (Switzerland), 2021, 6, 21.	1.7	O
6	Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes. Neurology, 2021, 96, 592-592.	1.1	0
7	Author Response: Deep Brain Stimulation in Early-Stage Parkinson Disease: Five-Year Outcomes. Neurology, 2021, 96, 591.1-591.	1.1	0
8	Enhancing Performance of a Spasticity Screening Tool Using the Minimum Data Set. Journal of the American Medical Directors Association, 2021, , .	2.5	0
9	Early subthalamic nucleus deep brain stimulation in Parkinson's disease reduces long-term medication costs. Clinical Neurology and Neurosurgery, 2021, 210, 106976.	1.4	6
10	Exploring the presence of multiple abnormal non-motor features in patients with cervical dystonia. Journal of Clinical Neuroscience, 2021, 94, 315-320.	1.5	1
11	BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics, 2020, 17, 1785-1795.	4.4	12
12	A Simple Bedside Screening Tool for Spasticity Referral. Clinical Interventions in Aging, 2020, Volume 15, 655-662.	2.9	4
13	Deep brain stimulation in early-stage Parkinson disease. Neurology, 2020, 95, e393-e401.	1.1	75
14	Prevalence of Spasticity in Nursing Home Residents. Journal of the American Medical Directors Association, 2020, 21, 1157-1160.	2.5	8
15	Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology, 2018, 91, e463-e471.	1.1	55
16	Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations. Journal of Parkinson's Disease, 2018, 8, 421-428.	2.8	6
17	Impact of Tremor on Patients With Early Stage Parkinson's Disease. Frontiers in Neurology, 2018, 9, 628.	2.4	30
18	Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 89-94.	2.8	10

#	Article	IF	CITATIONS
19	Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson's Disease Is Not Associated with Increased Body Mass Index. Parkinson's Disease, 2017, 2017, 1-4.	1.1	4
20	Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 125-131.	2.8	26
21	Deep brain stimulation in early stage Parkinson's disease may reduce the relativeÂrisk of symptom worsening. Parkinsonism and Related Disorders, 2016, 22, 112-113.	2.2	7
22	Deep brain stimulation in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 347-348.	2.2	10
23	Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1177-1183.	2.2	41